ABSTRACT

Objectives: Aim of the study was to describe the use and pharmacoutilization profiles of recommended drugs for HF patients, hospital re-admission rates, mortality rates and determine healthcare resource consumption and related costs for HF patients in an Italian region.

Methods: We retrospectively analyzed data from the administrative database and included adult patients who were discharged alive with a primary or secondary HF diagnosis between 1 January 2010 and 31 December 2015. We assessed data on HF-related drug prescriptions at discharge and during a 12-month follow-up period, as well as treatment adherence and treatment modification. All-cause mortality, hospital HF re-admission, and mean direct cost per patient were also analyzed during the follow-up period.

Results: A total of 69,164 patients were included. One in ten patients had discontinued all treatment initially prescribed by the end of follow-up. In total, 25.9% of patients were re-hospitalized with an HF diagnosis during the follow-up period; the mortality rate at 12 months was 24.3%. The mean annual cost per patient was €6,303.7, with nearly three-fourths attributable to hospitalizations.

Conclusions: In our study, we observed an under-prescription of recommended drugs for the treatment of HF. Moreover, one out of four HF patients were re-hospitalized for HF-related causes and the healthcare costs related to hospitalization accounted for the great majority of the total healthcare resource costs.

摘要

目的：本研究的目的是描述意大利地区心衰患者推荐药物的使用和药物利用概况，医院再入院率，死亡率，并确定心衰患者的医疗保健资源消耗和相关费用。

方法：我们回顾性分析了行政数据库中的数据，纳入了在2010年1月1日至2015年12月31日期间初次或继发HF诊断出世的成年患者。我们评估了出院时和12天内的HF相关药物处方数据一个月的随访期，以及治疗依从性和治疗修改。在随访期间，还分析了全因死亡率，再次入院HF和每位患者的平均直接费用。

结果：共纳入69,164例患者。十分之一的患者在随访结束时中断了最初规定的所有治疗。在随访期间，总共有25.9％的患者被院方确诊为HF。12个月时的死亡率为24.3％。每位患者的平均年费用为6,303.7欧元，近四分之三归因于住院治疗。

结论：在我们的研究中，我们发现用于治疗HF的推荐药物处方不足。此外，四分之一的心衰患者因心衰相关原因而再次入院，与住院相关的医疗费用占医疗资源总费用的绝大部分。